Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

June 30, 2022

Conditions
Tuberculosis, PulmonaryTuberculosis
Interventions
DRUG

Atorvastatin with standard anti tuberculosis drugs

Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight

DRUG

Standard anti tuberculosis drugs only

Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight

Trial Locations (2)

Unknown

Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife

Birmingham Heartlands Hospital, Birmingham

All Listed Sponsors
collaborator

University Hospital Birmingham NHS Foundation Trust

OTHER

collaborator

Cures Within Reach

OTHER

lead

Obafemi Awolowo University Teaching Hospital

OTHER

NCT04721795 - Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis) | Biotech Hunter | Biotech Hunter